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Abstract 
Aldosterone hypersecretion in primary aldosteronism is unilateral (aldosterone producing 
adenoma and primary unilateral hyperplasia) or bilateral (idiopathic adrenal hyperplasia). 
Laparoscopic adrenalectomy is nowadays the preferred approach to treat patients with 
unilateral primary aldosteronism. We review the outcomes of this intervention in recently 
published series. Laparoscopic adrenalectomy has a morbidity of 5 to 14%, mortality below 
1% and a mean hospital stay around 3 days. It generally results in the normalization of 
aldosterone secretion and in a large decrease of blood pressure and antihypertensive 
medication, but normotension without treatment is only achieved in 42% of all cases. 
Normotension following adrenalectomy is more likely in young and lean women with recent 
low grade hypertension than in obese men with long-standing high grade hypertension or a 
family history of hypertension. However, individual prediction of the blood pressure outcome 
is not accurate and predictors of hypertension cure should not be used to select patients for 
surgery. Age, associated health conditions and preferences of the patient are more relevant to 
this end. 
 
Keywords 
Hyperaldosteronism; Adrenalectomy; Minimally Invasive Surgical Procedures; Treatment 
Outcome; Prognosis; Spironolactone. 
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Introduction 
Aldosterone hypersecretion in primary aldosteronism (PA) can be bilateral (idiopathic adrenal 
hyperplasia or IAH) or unilateral (aldosterone producing adenoma or APA, primary unilateral 
hyperplasia or PUH). APA is a benign tumor varying  in  diameter  from  7  to  35  mm, with 
no burden directly related to the space occupied and no risk of malignant transformation [1]. 
PUH can be diffuse or nodular, with poorly capsulated nodules ranging from microscopic to 6 
mm [2];  in the latter case, the term “unilateral micronodular hyperplasia” may be used. 
 
The goals of treatment in PA are to reduce the morbidity and mortality associated with 
sustained aldosterone hypersecretion and to improve the patients’ quality of life. Health 
consequences of PA are partly mediated by high BP and low serum potassium. However, the 
cardiovascular and renal consequences of high BP are more severe in patients with PA than in 
patients with essential hypertension and similar levels of office BP. It is therefore assumed 
that sustained aldosterone hypersecretion induces target organ damage through genomic 
effects mediated by the mineralocorticoid receptor and possibly also by direct, non genomic 
effects [3].  
 
Treatment objectives in patients with PA are therefore to reduce BP, correct hypokalemia, and 
to prevent or reverse the cardiovascular and renal alterations directly caused by aldosterone 
excess. The most logical way to achieve these objectives in patients with unilateral PA is to 
suppress aldosterone hypersecretion by removing the culprit adrenal. Although aldosterone 
antagonists have the theoretical disadvantage of preventing only the genomic effects of 
hyperaldosteronism, they are a suitable alternative in patients who refuse or are not candidate 
for surgery. 
 
In the following sections we will firstly describe laparoscopic adrenalectomy and its 
morbidity; secondly we will consider potential alternative interventions to treat unilateral PA; 
thirdly we will summarize the outcomes and outcome predictors of laparoscopic 
adrenalectomy in these patients, with reference to medical treatment whenever possible. 
 
Laparoscopic adrenalectomy 
 
Since the first description of laparoscopic adrenalectomy in 1992 [4], the approach of adrenal 
surgery has been totally modified and laparoscopy has become the gold standard owing to its 
lower morbidity and shorter hospital stays. Subsequently, there was a significant increase of 
the proportion of patients with PA referred for minimally invasive adrenalectomy (27% after 
the introduction of laparoscopy vs. 13% before, p<0.05) [5]. 
 
Practical details 
 
To preclude the risk of hypokalemia-induced arrhythmia during anesthesia, hypokalemic 
patients should be provided potassium chloride or aldosterone antagonists before surgery [6]. 
Aldosterone antagonists may also suspend the chronic suppression of aldosterone secretion in 
the contralateral gland and thereby prevent postoperative hypoaldosteronism. Except 
comorbidities that could contraindicate laparoscopy per se, there is no technical reason that 
can avert from unilateral laparoscopic adrenalectomy for PA [7]. Obesity is not a contra-
indication but operating time correlates with the body mass index for both the transperitoneal 
or retroperitoneal laparoscopic approaches [8].  
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A large series illustrated the drawbacks and advantages of both approaches [9]. The lateral 
transperitoneal laparoscopic approach provides a wider exposure and therefore a more 
complete exploration of the abdomen, whereas the retroperitoneal approach avoids difficult 
exposure due to adhesions in patients with previous intra-abdominal surgery. This study 
shows that both approaches have similar outcomes when patients are well selected. The mean 
operating time of laparoscopic adrenalectomy, the rate of complications and the length of 
hospital stay vary depending on the indication and the approach used. The mean operative 
time of laparoscopic adrenalectomy in major institutional series is a between 2 to 3 hours, 
with a 3.4% conversion rate to open surgery and a mean hospital stay around 3 days [10].  
 
Laparoscopic adrenalectomy usually requires three to four ports to introduce the instruments. 
Although technically challenging, laparoscopic single-port surgery using the transumbilical 
approach is less invasive [11]. Robot-assisted laparoscopy is feasible and safe but more 
expensive and without documented advantage over conventional laparoscopy [12,13]. 
 
Outpatient laparoscopic adrenalectomy is possible [14]. The feasibility conditions are: a 
disease other than pheochromocytoma, age younger than 65 years, tumor size smaller than 6 
cm, no significant cardio-respiratory diseases, first case of the day to be managed in the 
surgical program, residence less than 30mn from the hospital by car, and no more than three 
antihypertensive agents. Over 22 outpatient procedures, the mean operating time was 57 min 
(range 15-120 min), the most frequent complications were pain and nausea.  
 
Morbidity 
 
The assessment of surgical morbidity is difficult because of the lack of standardized 
classification. The pooled mortality in major institutional series published up to 2005 (all 
indications confounded) was 0.4% (4/1083) [10]. There was no periprocedural death in the 
largest series published afterwards (0/520) [15]. The incidence of non fatal complications 
ranges from 5 to 14% [6,10]. The most frequent severe complication of laparoscopic 
adrenalectomy is bleeding requiring transfusion or conversion to open surgery [10]. 
Compared with open adrenalectomy, the rate of wound, infectious, and pulmonary 
complications is much lower. In the large series already mentioned, major complications 
occurred in 1.3% of patients (7/520: pneumothorax, pneumonia, myocardial infarction, heart 
failure, blood loss requiring transfusion) and minor complications in 14.4% (mainly 
temporary relaxation and/or hypoesthesia of abdominal wall) [15]. Laparoscopic 
adrenalectomy appears to have a low morbidity but the teams that report their data are usually 
very experienced, with only one or two specialized surgeons operating all patients. Several 
cases of major complications outside referral centers have been reported [16].  
 
Alternatives to laparoscopic adrenalectomy 
 
Other surgical approaches 
 
Partial adrenalectomy is an alternative to total adrenalectomy. It can be advocated since APA 
is always benign, and usually small, solitary, and located peripherally on the outer surface of 
the adrenal cortex. Moreover the adjacent cortex is always functioning, either normal or 
hyperplasic but never atrophied [17]. However, the rationale of partial adrenalectomy is still 
disputed since 10 to 25% of patients with unilateral PA have multiple adjacent nodules and 
there is no mean to be sure that the bigger lesion is the one responsible of the hypersecretion 
[2,18,19]. A review of 22 series (417 patients) found no unexpected complication of partial 
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adrenalectomy and similar surgical outcomes to total adrenalectomy [20]. A recent 
randomized controlled trial compared partial and total laparoscopic adrenalectomy in 212 
patients with APA [21]. The operative time was the same for both approaches but blood 
losses were significantly higher with partial adrenalectomy, although no transfusion was 
needed. No major complication was observed with either approach. In the end, partial 
adrenalectomy is feasible and safe to remove an APA. However, the benefit of this adrenal 
sparing approach is questionable because the risk of a contralateral tumor that would 
subsequently require adrenalectomy is very low in patients with an APA. In addition 
 
Non surgical approaches 
 
Several alternatives to surgery have also been proposed for unilateral PA, such as 
percutaneous ethanol injection, arterial embolization and more recently percutaneous 
radiofrequency ablation. The risk of failure and the lack of pathological examination of the 
adrenal are the main drawback of these techniques. The main exclusion criteria for these 
procedures are a tumor over 4 cm, out of reach or ill-located (close to the aorta, to the 
kidney…). The treatment of APA with one to three ethanol injections in five patients cured 
PA with no other complication than periprocedural pain [22]. Selective adrenal arterial 
embolization in 33 patients with an APA resulted in a decrease of more than 20UH of the 
adrenal and the cure rate of PA was 82% [23]. Most patients experienced flank pain after the 
procedure, 30% had fever, 30% had labile blood pressure, and 15% had pleural effusion. A 
series of 24 patients that did undergo CT-guided percutaneous radiofrequency ablation for 
APA has been reported [24]. Adenomas remained hypolucent without contrast enhancement 3 
to 6 months after the procedure in 100% of the patients and PA was cured in 96% (23/24 
patients). However the complication rate was 17% with one small pneumothorax and 3 
retroperitoneal hematomas 
 
Outcomes of laparoscopic adrenalectomy  
 
In this chapter we summarize the results observed in series published since 2000 with ≥ 50 
consecutive patients from a single institution operated for unilateral PA (Table 1). Patients 
from these series were almost all operated after 1992. Older series are unlikely be 
representative of current practice because (i) the threshold of hypertension was lowered to 
140/90 mmHg by the JNC5 in 1992 [25]; (ii) the aldosterone:renin ratio is widely used as a 
screening tool, independently of serum potassium levels, since 1990-1995 [26]; and (iii) 
laparoscopic adrenalectomy was first reported in 1992 and has become the preferred 
procedure since then [4]. Owing to these three changes, the clinical profile of PA patients who 
are sent to surgery is different since 1992 than it was before. It should be noted that patients 
from these series were assessed after medium term follow up (from a few months to a few 
years). Evidence is lacking regarding long term outcomes and especially the incidence of 
recurrent PA. 
 
Potassium and hormonal outcomes 
 
Surgery cures hypokalemia in > 95% PA and abolishes aldosterone hypersecretion in > 90% 
in patients with unilateral PA [33,35,36,39,43,45]. Persistent hyperaldosteronism is possible 
after surgery even if adrenal venous sampling (AVS) was performed to ascertain lateralization 
[33,45], as also reported in smaller series [46-48]. 
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Blood-pressure outcome 
 
Adrenalectomy produces a large decrease in systolic BP (typically -25 to -40 mmHg) and in 
the number of antihypertensive medications prescribed (typically -1 to -2 drug classes) [28-
32,37-39,41,44]. However, BP changes are highly dependent on medication changes and only 
one study proposed to make a composite outcome out of these two variables [31]. This BP 
outcome score was neither derived from nor validated on actual patient data; its validity 
therefore remained to be evaluated. One single study attempted to predict the BP decrease 
after surgery [32]. However, it did not take medication changes into account and the 
predictors were weak. For instance, the mean systolic BP decrease was -25 mmHg after 
surgery and was only 3 mmHg less (-22 instead of -25 mmHg) in patients with a 0.5 mmol/l 
higher level of serum potassium before surgery, the most powerful predictor of unfavorable 
outcomes [32]. 
 
Patients should be warned that hypertension is not always cured. The pooled cure rate was 
42% with significant heterogeneity across the series included in this review (Figure 1). Even 
when adrenalectomy does not cure hypertension, it usually leads to a clinically relevant 
improvement in the control of hypertension, with lower BP levels and/or less antihypertensive 
medication required. As a result, hypertension was cured or improved in 74 to 100% of cases 
in the series included in this review (Table 1). However, the definition of improvement 
differed in each series, precluding any pooled estimate of its occurrence. 
 
Many predictors of hypertension cure or persistence have been reported (Table 2). 
Considering only factors that remained significant in at least one multivariate analysis, 
hypertension is less likely to be cured after adrenalectomy in patients with unilateral PA who 
are males, older, with a family history of hypertension, longer duration of hypertension, 
higher preoperative BP, more drug classes, higher BMI, higher serum potassium 
concentrations, lower estimated GFR, higher 24-h urinary aldosterone/active renin ratio, or 
evidence of arteriolosclerosis (Table 2). Of note, having unilateral PA ascertained by AVS 
was never found to be a predictor of good outcome after surgery [27,44], and has even been 
associated with worse outcomes [32,33]. Likewise, among patients with unilateral PA 
diagnosed by AVS, those with higher a lateralization index do not have a better outcome [41]. 
 
The relevance of these predictors of hypertension cure for selecting patients for surgery 
should not be overemphasized. First, the validity of multivariate analyses is threatened by 
small sample sizes and several studies found no association with hypertension cure for each of 
the supposed predictors (Table 2). Second, the multivariate models provide only a weak 
prediction of hypertension cure in individual patients. For example, according to the only 
prediction model validated to date, number of antihypertensive medication ≤ 2, a body mass 
index ≤ 25 kg/m², a duration of hypertension ≤ 6 years and female sex are the best predictors 
of hypertension cure following adrenalectomy [34]. However, even if none of these features 
was present in an individual patient, he still had a 25% probability of being completely cured 
by an adrenalectomy in the validation cohort. Third, the focus on hypertension cure obscures 
the likely cure of hypokalemia and hyperaldosteronism and improvement of BP levels 
achieved even in patients with persistent hypertension after surgery. 
 
No study has directly compared the BP outcome in patients with unilateral PA treated with 
spironolactone vs. adrenalectomy. However, the increase in serum potassium and decrease in 
BP reported in patients with unilateral PA treated with spironolactone are similar to those 
reported with adrenalectomy, even after a long follow-up duration [49]. 
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Other outcomes 
 
Many studies have shown that the structural heart changes seen in patients with primary 
aldosteronism – mostly left ventricular hypertrophy – resolve or greatly improve after 
adrenalectomy [50-54]. Although spironolactone may appear less potent than adrenalectomy 
in improving left ventricular hypertrophy [51,52,55], studies with longer follow-up have 
shown that the improvement is slower but similar at the end [54]. A prospective study with 
long follow up compared PA patients who were treated by adrenalectomy (unilateral disease) 
or spironolactone (unilateral or bilateral disease) to patients with essential hypertension [56]. 
The composite endpoint – myocardial infarction, stroke, any type of revascularization 
procedure, and sustained arrhythmias – did neither differ between these patients with PA who 
received a specific treatment and patients with essential hypertension, nor did it differ 
between PA patients treated with adrenalectomy or spironolactone. 
 
Compared to otherwise similar patients with essential hypertension, patients with PA have a 
relative glomerular hyperfiltration that translates into increased GFR and low grade urinary 
albumin excretion. These changes are reversible after adrenalectomy in patients with 
unilateral PA [57-64]. Because of the reversal of relative hyperfiltration, adrenalectomy often 
unmasks hypertensive kidney disease with moderately decreased GFR. These results are also 
observed in PA patients treated with spironolactone [58-60,63,64]. 
 
Taken as a whole, patients with PA seem to have the same likelihood of glucose metabolism 
disorders than otherwise similar patients with essential hypertension [65,66]. Biochemical 
indexes of insulin resistance may improve after adrenalectomy [52,59], but this does not 
appear to translate into a clinically significant improvement of glucose metabolism [65].  
 
One single study evaluated the impact of adrenalectomy on the quality of life in unilateral PA: 
patients experienced a significant improvement of their subjective well-being, which was 
lower than in the general population pre-operatively [67]. Unexpectedly, patients with PA 
treated with spironolactone experience a comparable benefit, although the improvement in 
quality of life appears to be slower [68]. 
 
Benefit – risk and cost – effectiveness assessment 
 
As we have just seen, reduction of BP, correction of hypokalemia, and prevention or reversal 
of the cardiovascular and renal alterations can be achieved in patients with unilateral 
aldosterone hypersecretion by adrenalectomy or by the long-term prescription of aldosterone 
antagonists. Patients’ preferences should be taken into account. Candidates for surgery should 
be told that the presence of an aldosterone-producing adenoma poses no threat of cancer and 
informed about the expected outcomes of surgery (benefits and risks, see above).  
 
A primitive cost-effectiveness analysis performed for 50-year old PA patients found that 
adrenalectomy, with a 35% cure rate and a 85% improvement rate, was a cost saving option 
thanks to lifelong drugs withdrawal [69]. Younger patients have a longer life expectancy and 
therefore derive an even greater benefit from surgery. They also carry the smallest anesthetic 
risk. Early diagnosis of unilateral PA is therefore important. Patients with resistant 
hypertension may also derive a significant benefit, especially if compliance is an issue or if 
spironolactone is ineffective or not well tolerated. The benefit-risk ratio is more balanced in 
older patients, especially if their antihypertensive medication has compelling indications and 
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must be continued irrespective of BP levels, such as beta-blockers for coronary artery disease 
or angiotensin-converting enzyme and spironolactone for heart failure. 
 
Conclusion 
Laparascopic adrenalectomy is an appealing therapeutic option for patients with unilateral 
PA. Some factors are statistically associated with hypertension cure after adrenalectomy but 
should not be used to select patients for surgery because they fail to identify a significant 
number of patients that will be cured. Moreover, they ignore the large BP and/or medication 
decrease and the direct benefit associated with the suppression of aldosterone hypersecretion 
in patients who remain hypertensive after adrenalectomy. Only the few patients who are at 
high surgical risk and those with a short life expectancy should be advised against surgery. On 
the other hand, patients should not be pressed to undergo surgery if they prefer not to, because 
a fair body of evidence suggests that lifelong treatment with mineralocorticoid antagonists is a 
valuable alternative to surgery. Other medical options, like aldosterone synthase inhibitors, 
may also be available in the near future. Best practice is to discuss treatment options with the 
patient even before performing AVS.  
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Table 1. Series published since 2000 with blood pressure follow-up after adrenalectomy for unilateral PA in at least 50 consecutive 
patients 
 
Institution 
Years of 
inclusion 
Patients 
followed 
Patients 
cured Definition of improvement 
Patients 
cured or 
improved 
Rochester, Mayo Clinic [23] 1993-1999 93 31 (33%) BP decrease or fewer drugs 92 (99%) 
Padova, University hospital [24] 1988-2002 98 71 (72%) Less medication required for BP control 95 (97%) 
Tokyo and Yokohama, Social Insurance 
Central General Hospital and Yokohama 
Rosai Hospital [25] 
1995-2005 69 44 (64%) None provided Not 
available 
Sendai, Tohoku University Hospital [26] Not 
available 
61 23 (38%) BP decrease 61 (100%) 
Sydney, University of Sydney Endocrine 
Surgical Unit [27] 
1995-2005 53 18 (34%) BP < 140/90 mmHg with equal or fewer 
drugs, or hypertensive but requiring fewer 
drugs 
48 (91%) 
Padova, University hospital [28] Not 
available 
50 15 (30%) BP < 140/90 mmHg or fall of systolic and/or 
diastolic BP > 10%, on the same or reduced 
number of drugs and/or daily doses 
50 (100%) 
Paris, HEGP [29] 1993-2004 168 53 (32%) Systolic BP < 140 mmHg and/or diastolic 
BP < 90 mmHg or diastolic BP decrease ≥ 
15 mmHg, for patients remaining on the 
same or less medication 
124 (74%) 
San Francisco, University of California 
San Francisco [30,31] 
1994-2005 100 35 (35%) BP decrease or fewer drugs 95 (92%) 
Essen, Kliniken Essen-Mitte [32] 1994-2007 160 48 (30%) a Systolic BP ≤ 140 mmHg with reduced 
medication 
139 (87%) 
Ann Harbor, University of Michigan [33] 1996-2007 62 10 (16%) BP < 140/90 mmHg with medication 53 (85%) 
Paris, Broussais [34] 1997-1999 58 23 (40%) BP < 140/90 mmHg with medication 43 (74%) 
Taiwan, Chang Gung University College 
of Medicine [35] 
1987-2006 52 32 (62%) None provided Not 
available 
Ancona, Polytechnic University of 1994-2006 54 21 (39%) a Systolic BP ≤ 140 mmHg with reduced 47 (87%) 
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Marche [36] medication 
Taiwan, University Hospital [37] 1999-2007 150 95 (63%) b BP decrease with lower dosages of drugs 145 (97%) 
Philadelphia, University of Pensylvania 
[38] 
2001-2007 57 12 (21%) Systolic BP decrease > 10 mmHg with the 
same number of drugs, or SBP within 10 
mmHg from preoperative value with fewer 
drugs 
51 (89%) 
Paris, Pitié Salpétrière [39] 1997-2008 57 33 (58%) Fewer drugs 56 (98%) 
Wuhan, Tongji Hospitals [40] 2002-2007 93 54 (58%) None provided Not 
available 
Marburg, University Hospital Giessen and 
Marburg [41] 
1993-2009 54 20 (37%) None provided Not 
available 
 
BP: blood pressure. Patients cured if BP < 140/90 mmHg without medication except a systolic BP < 140 mmHg without medication and b BP < 
140/90 mmHg without medication in more than 75% of measurements 
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Table 2. Predictors of hypertension cure following adrenalectomy in series published since 2000 and including at least 50 consecutive 
patients 
 
Risk factor 
Associated in univariate 
analysis 
Associated in 
multivariate analysis Not associated 
Being female 4 studies [32] [27] [39] 
[36] 
1 study [31] 7 studies [37] [28] [24] 
[23] [38] [41] [40] 
Younger age 5 studies [32] [39] [36] 
[23] [41] 
5 studies [37] [31] [27] 
[24] [34] 
4 studies [28] [35] [38] 
[40] 
Absence of diabetes 1 study [37] No study No study 
Absence of cardiovascular disease 1 study [37] No study No study 
No history of essential hypertension in first-
degree relatives 
2 studies [37] [36] 2 studies [23] [40] 3 studies [31] [39] [24] 
Shorter duration of hypertension before surgery 5 studies [32] [31] [39] 
[36] [23]  
5 studies [37] [28] [24] 
[40] [41] 
2 studies [35] [34] 
Lower preoperative BP 3 studies [28] [39] [35]  2 studies [37] [40] 5 studies [27] [24] [23] 
[38] [41] 
Lower number of prescribed antihypertensive 
classes 
5 studies [27] [39] [36] 
[24] [38] 
3 studies [31] [23] [41] 4 studies [37] [28] [35] 
[40] 
Preoperative normalization of BP 1 study [30] No study No study 
Preoperative normalization of BP on 
monotherapy with high-dose spironolactone 
No study No study 2 studies [30] [24] 
Lower body mass index or weight 3 study [28] [39] [41] 2 studies [37] [31] 2 studies [24] [40] 
Low serum potassium levels 1 study [31] 1 study [34] 9 studies [37] [27] [28] 
[39] [35] [24] [23] [41] 
[40] 
Higher estimated GFR or lower creatinine 
concentration 
2 studies [39] [34] 2 studies [37] [41] 4 studies [35] [24] [38] 
[40] 
Presence of proteinuria No study No study 1 study [37] 
Higher left ventricular mass index 1 study [34] No study 1 study [28] 
Presence of arteriolosclerosis No study 1 study [28] No study 
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Higher urinary aldosterone excretion 1 study [23] No study 1 study [34] 
Higher 24-h urinary aldosterone/active renin 
ratio 
No study 1 study [34] No study 
Higher plasma aldosterone concentration No study No study 10 studies [37] [31] [27] 
[39] [35] [24] [34] [38] 
[41] [40] 
Lower plasma renin concentration or activity 2 studies [31] [39] No study 5 studies [37] [35] [34] 
[38] [40] 
Higher aldosterone:renin ratio 2 studies [34] [23] No study 8 studies [37] [31] [28] 
[39] [35] [24] [38] [40] 
Furosemide upright test 1 study [25] No study No study 
Captopril test 1 study [25] No study No study 
Typical adenoma on imaging or pathology 2 studies [32] [31] No study 4 studies [37] [39] [23] 
[38] 
Larger adenoma 3 studies [31] [39] [34]  No study 5 studies [27] [28] [24] 
[41] [40] 
Smaller adenoma 1 study [25] No study 5 studies [27] [28] [24] 
[41] [40] 
Smaller adrenal gland 1 study [27] No study No study 
Lateralization established by CT rather than 
AVS 
1 study [30] [29] No study 2 studies [23] [41] 
Higher lateralization index No study No study 1 study [38] 
Adenomectomy (vs. adrenalectomy) 1 study [32] No study No study 
 
BP: blood pressure; GFR: glomerular filtration rate; CT: computed tomography; AVS: adrenal venous sampling 
 
 
    Overall  (I-squared = 89.8%, p = 0.000) 
Sawka (2001) 
Wang (2010) 
Waldman (2011) 
Wu (2009) 
Zarnegar (2008) 
Satoh (2007) 
Letavernier (2008) 
Mourad (2008) 
Trésallet (2010) 
Pang (2007) 
Walz (2008) 
Murashima (2009) 
Lumachi (2005) 
Chiou (2009) 
Campagnacci (2009) 
Rossi (2008) 
Omura (2006) 
White (2008) 
93 
93 
54 
150 
100 
61 
168 
58 
57 
53 
160 
57 
98 
52 
54 
50 
69 
62 
31 (33%) 
54 (58%) 
20 (37%) 
95 (63%) 
35 (35%) 
23 (38%) 
53 (32%) 
23 (40%) 
33 (58%) 
18 (34%) 
48 (30%) 
12 (21%) 
71 (72%) 
32 (62%) 
21 (39%) 
15 (30%) 
44 (64%) 
10 (16%) 
  
25% 50% 75% 
42% 
Patients 
followed 
Patients 
cured 
